戻る Agendas
[V1-S3] For Enhancement of Industry-Government-Academia Collaboration in Japan (Part 1)
Session Chair(s)
Hideki Hanaoka, MD, PhD
Chiba University Hospital Clinical Research Center, Japan
Toshio Miyata, MD
Executive Director
Health and Global Policy Institute, Japan
In April 2015, AMED, Japan Agency for Medical Research and Development, was established to enhance efficient research and development, from the basic scientific research to practical application, with consistency in the field of health care science in Japan. Creating innovative drugs from Japan is one of the most important elements of Japan’s growth strategy and a great chance for pharmaceutical industry at the same time. In this session, experts from academic departments, industry, and government will facilitate discussions on the challenges we have in collaboration among them, sharing the excellent practices from several ongoing activities.
Speaker(s)
AMED’s Support for Translational Researches, Clinical Researches, and Clinical Trials
Yasunori Yoshida
Cabinet Office, Government of Japan, Japan
Food Safety Commission of Japan
Activity of Duke Clinical Research Institute
John H. Alexander, MD
Duke Clinical Research Institute, United States
Director, Cardiovascular Research; Vice Chief, Clinical Research, Cardiology
A case of succeeded program designed to novel industry-government-academia collaboration
Michihiko Wada, MD, PhD
Clinical and Translational Research Center, Keio University, Japan
Professor